Inspiratory efforts achieved in use of the Technosphere® insulin inhalation system

Journal of Diabetes Science and Technology

Volumn 3, Issue 5, 2009, Pages 1175-1182

  Smutney, Chad C ^a   Friedman, Emil M ^a   Polidoro, John M ^b   Amin, Nikhil ^c  

^a MannKind Corporation   (United States)

^b aVisionary Company   (United States)

^c MannKind Corporation   (United States)

Author keywords

Diabetes; Inhalation effort; Inhaled insulin; Inhaler; Technosphere insulin

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; FEMALE; HUMAN; INHALATION; INHALATIONAL DRUG ADMINISTRATION; INSTRUMENTATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; MULTICENTER STUDY; NEBULIZER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; POWDER; PRESSURE; RANDOMIZED CONTROLLED TRIAL; TIME; UNITED STATES;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INHALATION; INSULIN; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POWDERS; PRESSURE; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 77953064007     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680900300524     Document Type: Article

References (14)

1. Skylar JS, Jovanovic L, Klioze S, Reis J, Duggan W, Inhaled Human Insulin Type 1 Diabetes Study Group. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care. 2007;30(3):579-85. (Pubitemid 46354337)
2. Moses RG, Bartley P, Lunt H, O'Brien RC, Donnelly T, Gall MA, Vesterager A, Wollmer P, Roberts A. Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with type 1 diabetes: 1-year data from a randomized, parallel group trial. Diabet Med. 2009;26(3):260-7.
3. De Koning JP. Dry powder inhalation: technical and physiological aspects, prescribing and use. Dissertation. University of Groningen. http://irs.ub.rug.nl/ppn/216544823.
4. Rosenstock J, Bergenstal R, Defronzo RA, Hirsch IB, Klonoff D, Boss AH, Kramer D, Petrucci R, Yu W, Levy B, 0008 Study Group. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008; 31(11):2177-82.
5. Bergenstal RM, Kapsner PL, Rendell MS, Boss AH, Howard CP, Chang P-C, Richardson PC. Comparative efficacy and safety of Afresa and a rapid-acting analog both given with glargine in subjects with T1DM in a 52-week study. Poster presentation at the 69th annual meeting of the American Diabetes Association, June 2009.
6. Amin N, Boss AH, Petrucci RE, Phillips MD, Richardson PC. Pulmonary functions (over 2 years) in diabetic subjects treated with Afresa or usual antidiabetic treatment. Poster presentation at the 69th annual meeting of the American Diabetes Association, June 2009.
7. Rosenstock J, Lorber DL, Petrucci RE, Howard CP, Shearer DM, Bilheimer DW, Chang P-C, Richardson PC. Basal/bolus with prandial inhaled Technosphere Insulin plus insulin glargine QD vs. biaspart 70/30 insulin BID in T2DM inadequately controlled on insulin with/without oral agents. Poster presentation at the 69th annual meeting of the American Diabetes Association, June 2009.
8. Cassidy JP, Marino MT, Amin N, Gotfried M, Baughman RA, Gray MM, Boss AH, Richardson PC. Lung deposition and absorption of insulin from Afresa (Technosphere Insulin). Poster presentation at the 69th annual meeting of the American Diabetes Association, June 2009.
9. Potocka E, Baughman RA, Schwartz SL, Gray MM, Diaz MLM, Richardson PC. Pharmacokinetics of Afresa unchanged in patients with chronic obstructive pulmonary disease. Poster presentation at the 69th annual meeting of the American Diabetes Association, June 2009.
10. Howard CP, Rubin RR, Peyrot M. Patient reported outcomes in adults with type 2 diabetes using mealtime Afresa (inhaled Technosphere Insulin) and basal insulin versus premixed insulin. Poster presentation at the 69th annual meeting of the American Diabetes Association, June 2009.
11. Steiner S, Pfützner A, Wilson BR, Harzer O, Heinemann L, Rave K. Technosphere/insulin - proof of concept study with a newer formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes. 2002;110(1):17-21. (Pubitemid 34136277)
12. Pfützner A, Forst T. Pulmonary insulin delivery by means of the Technospshere drug carrier mechanism. Expert Opin Drug Deliv. 2005;2(6):1097-106.
13. Miller A, Thornton JC, Warshaw R, Anderson H, Teirstein AS, Selikoff IJ. Single breath diffusion capacity in a representative sample of the population of Michigan, a large industrial state. Am Rev Respir Dis. 1983;127:270-7.
14. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8(2):135-60. (Pubitemid 29425900)